Table 2 Risk factors of immune features for COVID-19 infection in patients with immune-compromise

Features

Asymptomatic/Mildn=95

Moderate/Severen=14

Univariable analysis P value

Lymphocyte, /μL

1364 (284-6382)

1084 (274-3107)

0.095

CD3+ T cell, /μL

1167 (254-6261)

706.5 (104-2113)

0.013

CD8+ T cell, /μL

628 (49-3913)

336 (51-1066)

0.022

CD4+ T cell, /μL

354 (60-3554)

307 (18-881)

0.108

CD19+ B cell, /μL

26 (0-1719)

24.5 (0-742)

0.436

NK cell, /μL

160 (3-1477)

95.5 (7-1869)

0.909

CD4+/CD8+ ratio

0.7 (0.1-2.8)

0.8 (0.3-2.3)

0.540

T and B cell subsets

0.893

 CD8^dom B^dep

33

5

 CD8^dom B⁺

32

3

 CD4/CD8^nor B^dep

16

3

 CD4/CD8^nor B⁺

10

2

 CD4^dom B⁺

4

1

CD8+ T cells

 Naïve, %

48.4 (6.1-97.2)

57.2 (1.7-86.1)

0.993

 TCM, %

16.3 (1.6-59.2)

24.1 (8.0-63.7)

0.194

 TEM, %

5.7 (0.2-55.8)

8.7 (1.2-32.1)

0.685

 TEMRA, %

13.3 (0.3-70.8)

9.0 (1.0-33.7)

0.404

CD4+ T cells

 Naïve, %

41.3 (2.6-92.5)

41.4 (1.0-70.6)

0.338

 TCM, %

37.4 (5.4-65.9)

41.8 (22.2-89.3)

0.016

 TEM, %

12.6 (0.3-65.2)

11.9 (4.6-45.7)

0.685

 TEMRA, %

1.1 (0-15.0)

1.0 (0-3.7)

0.525

B cells

 Naïve B, %

65.0 (0-97.1)

24.1 (0-97.8)

0.095

 Memory B, %

8.6 (0- 68.8)

11.6 (0-61.0)

0.807

 Plasmablast, %

1.6 (0-50.0)

5.6 (0-35.6)

0.864

 Transitional B, %

9.8 (0-76.7)

0.8 (0-69.2)

0.045